- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
RAS inhibitors, beta-blockers after discharge improve outcomes in MI with mid-range EF: Study
South Korea: The medical therapy with beta-blockers or RAS inhibitors at discharge is tied to better 2-year clinical outcomes in patients with mildly reduced left ventricular ejection fraction (EF) after acute myocardial infarction (AMI), states a recent study. The study was published in medRxiv.org as a preprint and has not yet been peer-reviewed.
There has been an increase in the number of patients with mildly reduced left ventricular ejection fraction (41 - 49%) in the era of the initial optimal interventional and medical therapy for acute myocardial infarction. Considering this, Seung-Jae Joo, Department of Internal Medicine, Jeju National University Hospital, Jeju, Republic of Korea, and colleagues aimed to investigate the association between the medical therapy with oral beta-blockers or inhibitors of the renin-angiotensin system (RAS) and 2-year clinical outcomes in patients with mildly reduced EF after AMI in an observational study.
For this purpose, propensity-score matched patients who survived the initial attack and had mildly reduced EF were selected according to beta-blocker or RAS inhibitor therapy at discharge among patients enrolled in the Korea Acute Myocardial Infarction Registry-National Institute of Health.
The study revealed the following findings:
- Beta-blocker therapy at discharge was associated with lower 2-year major adverse cardiac events which was a composite of cardiac death, myocardial infarction, revascularization and re-hospitalization due to heart failure (8.7 vs. 12.8/100 patient-years; hazard ratio [HR] 0.68), and no significant interaction between EF ≤45% and >45% was observed.
- This association was mainly driven by lower myocardial infarction in patients with beta-blockers (HR 0.50).
- Inhibitors of RAS at discharge were associated with lower re-hospitalization due to heart failure (1.8 vs. 3.5/100 patient-years; HR 0.53) without significant interaction between EF ≤45% and >45%.
"Our findings revealed that The medical therapy with beta-blockers or RAS inhibitors at discharge in patients with mildly reduced EF after AMI was associated with better 2-year clinical outcomes without significant interaction between EF ≤45% and >45%," wrote the authors.
"The data suggest that beta-blockers and RAS inhibitors can be considered in patients with mildly reduced LVEF after an acute MI in the era of early coronary reperfusion therapy and contemporary optimal medical therapies," they concluded.
Reference:
The preprint research study titled, "Association of the medical therapy with beta-blockers or inhibitors of the renin-angiotensin system with clinical outcomes in patients with mildly reduced left ventricular ejection fraction after acute myocardial infarction," appears in medRxiv.org.
DOI: https://doi.org/10.1101/2022.03.01.22271686
KEYWORDS: medRxiv.org, beta-blockers, RAS inhibitor, myocardial infarction, discharge, left ventricular ejection fraction, EF, acute MI, Seung-Jae Joo, MI, medical therapy, LVEF
MSc. Biotechnology
Medha Baranwal joined Medical Dialogues as an Editor in 2018 for Speciality Medical Dialogues. She covers several medical specialties including Cardiac Sciences, Dentistry, Diabetes and Endo, Diagnostics, ENT, Gastroenterology, Neurosciences, and Radiology. She has completed her Bachelors in Biomedical Sciences from DU and then pursued Masters in Biotechnology from Amity University. She has a working experience of 5 years in the field of medical research writing, scientific writing, content writing, and content management. She can be contacted at  editorial@medicaldialogues.in. Contact no. 011-43720751
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751